<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423683</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 06-034</org_study_id>
    <nct_id>NCT00423683</nct_id>
  </id_info>
  <brief_title>Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism</brief_title>
  <official_title>A Randomized Control Trial of Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With A Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of clots is a potentially deadly complication in many cancer patients. The
      current optimal treatment is unknown. Evidence supporting the effectiveness of the use of
      Inferior Vena Caval Filters is lacking. This study will compare the two standard of care
      treatment options: anticoagulation with or without a inferior vena cava filter. The
      anticoagulation medication chosen will be Arixtra and it will be given once a day as an
      injection. Patients will be called at various intervals to monitor their signs and symptoms
      of new thromboembolisms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of clots is a potentially deadly complication in many cancer patients. The
      current optimal treatment is unknown. Evidence supporting the effectiveness of the use of
      Inferior Vena Caval Filters is lacking. This study will compare the two standard of care
      treatment options: anticoagulation with or without an inferior vena cava filter. The
      anticoagulation medication chosen will be Arixtra and it will be given once a day as an
      injection. Patients will be called at various intervals to monitor their signs and symptoms
      of new thromboembolisms. Patients will be equally randomized to receive either Arixtra with
      or without placement of an Inferior Vena Cava (IVC) filter. Fifty three patients are expected
      to be enrolled in each arm. Patients will be monitored for 90 days after study enrollment.
      Monitoring will include telephone calls and physician visits and repeat radiologists if the
      patient is symptomatic of a Deep Vein thrombosis (DVT). This will also include completion of
      a quality of life questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study accrual stopped due to poor accrual.
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Outcomes</measure>
    <time_frame>3 years or until death</time_frame>
    <description>Rates of VCF complications, bleeding, and recurrent or residual DVTs or PEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years or until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of DVT</measure>
    <time_frame>3 years or until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of PE</measure>
    <time_frame>3 years or until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cancer</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>1- Arixtra Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arixtra Alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Arixtra+ filter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arixtra + filter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arixtra alone</intervention_name>
    <description>Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)</description>
    <arm_group_label>1- Arixtra Alone</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arixtra + filter</intervention_name>
    <description>Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.</description>
    <arm_group_label>2 Arixtra+ filter</arm_group_label>
    <other_name>IVC filter and Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of cancer.

          -  The disease may be a solid tumor, Lymphoma or Multiple Myeloma. Pathology reports will
             be documented in the patient's chart and included in the data.

          -  Age &gt; 18 years

          -  An acute, radiographically confirmed, de novo Deep Vein Thrombosis (DVT) or Pulmonary
             Embolism (PE)

          -  No past medical history of a prior thrombus or known thrombophilia

        Exclusion Criteria

          -  Patients are not eligible for this study if they receive therapeutic doses of any
             heparin for more than 72 hours before randomization 31.

          -  Already receiving oral anticoagulant therapy 31.

          -  Severe renal impairment, calculated using the Cockcroft-Gault formula, defined as a
             creatinine clearance &lt;30 mL/min 31.

          -  Platelet count of less than 50,000 per cubic millimeter

          -  Bleeding from the gastrointestinal tract that requires blood transfusion (s),
             intracranial bleeding or retroperitoneal bleeding.

          -  An indication for thrombolysis

          -  Allergy to iodine

          -  Hereditary thrombophilia

          -  Pregnancy

          -  Likelihood of noncompliance

          -  It is contraindicated to anticoagulate patients with brain metastasis secondary to
             melanoma, choriocarcinoma, renal cell and medullary thyroid carcinoma. If these
             patients have a Venous Thromboembolism (VTE), it is standard of care for these
             patients to have a CT of their head to evaluate if there is metastasis to the brain
             before they are anticoagulated 38. If these patients do have brain metastasis, they
             will not be included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myra Barginear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore University Hospital Monter Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel R. Budman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore University Hospital Monter Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>October 24, 2012</results_first_submitted>
  <results_first_submitted_qc>March 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2016</results_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Daniel Budman</investigator_full_name>
    <investigator_title>Interim Chief, Division of Oncology</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment was slowed due to newly approved medications so study was stopped early.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2 Arixtra+ Filter</title>
          <description>Arixtra subq injection + IVC filter</description>
        </group>
        <group group_id="P2">
          <title>1-Arixtra Alone</title>
          <description>Arixtra treatment without inferior vena cava filter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 Arixtra+ Filter</title>
          <description>Arixtra subq injection + IVC filter</description>
        </group>
        <group group_id="B2">
          <title>1- Arixtra Alone</title>
          <description>Arixtra treatment without inferior vena cava filter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="2"/>
                    <measurement group_id="B2" value="67" spread="14"/>
                    <measurement group_id="B3" value="65" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Outcomes</title>
        <description>Rates of VCF complications, bleeding, and recurrent or residual DVTs or PEs</description>
        <time_frame>3 years or until death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arixtra</title>
          </group>
          <group group_id="O2">
            <title>Arixtra and Filter</title>
          </group>
        </group_list>
        <measure>
          <title>Adverse Outcomes</title>
          <description>Rates of VCF complications, bleeding, and recurrent or residual DVTs or PEs</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>3 years or until death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Arixtra</title>
          </group>
          <group group_id="O2">
            <title>Arm 2 Arixtra + IVC Filter</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493" lower_limit="141" upper_limit="744"/>
                    <measurement group_id="O2" value="266" lower_limit="118" upper_limit="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of DVT</title>
        <time_frame>3 years or until death</time_frame>
        <population>33 participants contributed 59 DVT sites in Arm 1; 31 participants contributed 48 DVT sites in Arm 2. Unit of analysis was DVT sites</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Arixtra</title>
          </group>
          <group group_id="O2">
            <title>Arm 2 Arixtra + IVC Filter</title>
          </group>
        </group_list>
        <measure>
          <title>Resolution of DVT</title>
          <population>33 participants contributed 59 DVT sites in Arm 1; 31 participants contributed 48 DVT sites in Arm 2. Unit of analysis was DVT sites</population>
          <units>percentage of DVT sites</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>DVT sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of PE</title>
        <time_frame>3 years or until death</time_frame>
        <population>33 participants contributed 25 PE sites in Arm 1; 31 participants contributed 18 PE sites in Arm 2. Unit of analysis was PE sites</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Arixtra</title>
          </group>
          <group group_id="O2">
            <title>Arm 2 Arixtra + IVC Filter</title>
          </group>
        </group_list>
        <measure>
          <title>Resolution of PE</title>
          <population>33 participants contributed 25 PE sites in Arm 1; 31 participants contributed 18 PE sites in Arm 2. Unit of analysis was PE sites</population>
          <units>percentage of PE sites</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>PE sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2 Arixtra+ Filter</title>
          <description>Arixtra subq injection + IVC filter</description>
        </group>
        <group group_id="E2">
          <title>Arixtra Alone</title>
          <description>Arixtra anti coagulation alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Valerie Blake</name_or_title>
      <organization>North Shore LIJ Health System</organization>
      <phone>516-562-0100</phone>
      <email>vblake@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

